![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by 3 Beer Effect on June 23, 2002, at 17:42:53
I came across a medication listed on the internet that was in phase II clinical trials way back in the year 2000 for Attention Deficit Disorder. It was being developed by Glaxo SmithKline Beecham (GSK) formerly known as Glaxo Wellcome.
It is called GW320659 and is a norepinephrine/dopamine reuputake inhibitor.
Is this a less toxic, non-seizure causing, analog or improvement upon Wellbutrin SR?
Is there a name for this compound & what is the status of it in clinical trials, FDA approval etc?
Any other additional info about GW320659 or other upcoming improved/less toxic versions of Wellbutrin would be appreciated.
Thanks,
3 Beers.........
Posted by Bob on June 24, 2002, at 11:12:13
In reply to What is GlaxoSK GW320659 nor/dop reup inhib ADD?, posted by 3 Beer Effect on June 23, 2002, at 17:42:53
Why do you refer to Welbutrin as "toxic"? Is it more toxic than the other ADs?
Posted by medlib on June 24, 2002, at 13:05:28
In reply to What is GlaxoSK GW320659 nor/dop reup inhib ADD?, posted by 3 Beer Effect on June 23, 2002, at 17:42:53
Hi again 3B--
According to the GSK pipeline dated 5/17/02, GW320659 is still in Phase II, thus no name and no FDA activity yet. It's described as a beta 3 agonist; prelim rx indications for obesity, Type 2 diabetes, and/or ADHD.
Sorry--no kinder, gentler Wellbutrin on the immediate horizon that I know of---medlib
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.